Research demonstrates SREBF2 regulates fat and bone formation in bone marrow stromal cells, suggesting a new treatment target.
SREBF2 promotes osteoporosis by activating Hippo/YAP to drive adipogenesis while inhibiting BMP/Smad to suppress osteogenesis in BMSCs. Targeting SREBF2 is a promising therapeutic strategy.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: